Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL-33
- Development stage
- Phase 1
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
FL-33 is an investigational chimeric antigen receptor T cell (CAR T) therapy specifically engineered to target the CD33 antigen, which is commonly expressed on the surface of myeloid leukemia cells. The therapy involves collecting a patient's own T cells, genetically modifying them to express a CAR that recognizes CD33, and then infusing these modified cells back into the patient to attack and destroy cancerous cells. FL-33 is being evaluated for safety and efficacy in patients with refractory or relapsed acute myeloid leukemia (AML). It represents an optimized approach to targeting CD33-positive malignancies using cellular immunotherapy[1][2].
- Other names
- FL-33 CAR TFL33 CAR TFL 33 CAR TOptimised CD33 (FL-33) CAR T
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on FL-33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL-33.